Prof Research published a new market report on oncology drugs. It presents the 20 pharmaceutical leaders in the oncology drugs market. The report is a professional and in-depth study on the current state of the global oncology drugs market with a focus on the Chinese market. The report provides key statistics on the market of oncology drugs. It is a valuable source of guidance and direction for companies and individuals interested in the oncology drugs industry.

The global oncology drugs market was valued to be 143.0 billion USD in 2020. The oncology drugs market size is anticipated to have grown with a CAGR of1.7% in the coming years to reach264.3 billion USD in 2026. Roche, Merck & Co., Inc., Johnson & Johnson, Bristol Myers Squibb, Pfizer, Novartis, AbbVie, AstraZeneca are global top 8 players of oncology drugs and their total market share is 77.6%.

pembrolizumab, Ibrutinib, nivolumab, Palbociclib, Bevacizumab, osimertinib, daratumumab, pertuzumab, trastuzumab, pomalidomide, Rituximab, olaparib, abiraterone acetate, atezolizumab, Pemetrexed, dasatinib, durvalumab are the 17 oncology drugs which sales is more than 2 billion USD in 2020.

                                                                                                            Table Global Top 10 Oncology Drugs and Sales (million USD) in 2020